pI: 6.3884 |
Length (AA): 711 |
MW (Da): 80866 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 4 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 711 | 1ja1 (A) | 65 | 678 | 20.00 | 0 | 1 | 1.04458 | 0.56 |
13 | 710 | 2bpo (A) | 55 | 691 | 25.00 | 0 | 1 | 1.09782 | 0.57 |
19 | 204 | 4h2d (A) | 6 | 160 | 51.00 | 0 | 1 | 0.766703 | -1.02 |
484 | 613 | 2r6h (A) | 209 | 334 | 29.00 | 0.0039 | 0.84 | 0.137941 | 1.12 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Ortholog group members (OG5_128819)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT3G02280 | NADPH-dependent diflavin oxidoreductase ATR3 |
Babesia bovis | BBOV_IV009350 | flavodoxin domain containing protein |
Brugia malayi | Bm1_27745 | flavodoxin family protein |
Candida albicans | CaO19.9588 | similar to NAPDH-cytochrome P450 reductase |
Candida albicans | CaO19.2040 | similar to NAPDH-cytochrome P450 reductase |
Caenorhabditis elegans | CELE_Y113G7A.8 | Protein FRE-1 |
Dictyostelium discoideum | DDB_G0287983 | NADPH-dependent diflavin oxidoreductase 1 |
Drosophila melanogaster | Dmel_CG13667 | CG13667 gene product from transcript CG13667-RB |
Echinococcus granulosus | EgrG_001003200 | NADPH dependent diflavin oxidoreductase 1 |
Echinococcus multilocularis | EmuJ_001003200 | NADPH dependent diflavin oxidoreductase 1 |
Homo sapiens | ENSG00000188566 | NADPH dependent diflavin oxidoreductase 1 |
Leishmania braziliensis | LbrM.20.2230 | NADPH-cytochrome p450 reductase-like protein |
Leishmania donovani | LdBPK_342500.1 | NADPH-cytochrome p450 reductase-like protein |
Leishmania infantum | LinJ.34.2500 | NADPH-cytochrome p450 reductase-like protein |
Leishmania major | LmjF.34.2670 | NADPH-cytochrome p450 reductase-like protein |
Leishmania mexicana | LmxM.33.2670 | NADPH-cytochrome p450 reductase-like protein |
Loa Loa (eye worm) | LOAG_08813 | hypothetical protein |
Mus musculus | ensembl-mmu:ENSMUSG00000006471 | NADPH dependent diflavin oxidoreductase 1 |
Neospora caninum | NCLIV_065520 | hypothetical protein |
Oryza sativa | 4324160 | Os01g0733600 |
Saccharomyces cerevisiae | YPR048W | Tah18p |
Schistosoma japonicum | Sjp_0026940 | ko:K00327 NADPH-ferrihemoprotein reductase [EC1.6.2.4], putative |
Schistosoma mansoni | Smp_038820 | diflavin oxidoreductase |
Schmidtea mediterranea | mk4.006061.03 | NADPH-dependent diflavin oxidoreductase 1 |
Schmidtea mediterranea | mk4.017037.02 | NADPH-dependent diflavin oxidoreductase 1 |
Trypanosoma brucei gambiense | Tbg972.4.1870 | NADPH--cytochrome p450 reductase, putative |
Trypanosoma brucei | Tb927.4.1950 | NADPH-dependent diflavin oxidoreductase 1 |
Trypanosoma congolense | TcIL3000_4_1680 | NADPH--cytochrome P450 reductase, putative |
Trypanosoma cruzi | TcCLB.510877.120 | NADPH-dependent FMN/FAD containing oxidoreductase, putative |
Toxoplasma gondii | TGME49_249320 | flavodoxin domain-containing protein |
Theileria parva | TP01_0838 | hypothetical protein |
Gene/Ortholog | Organism | Phenotype | Source Study |
---|---|---|---|
Tb927.4.1950 | Trypanosoma brucei | no significant loss or gain of fitness in bloodstream forms (3 days) | alsford |
Tb927.4.1950 | Trypanosoma brucei | significant gain of fitness in bloodstream forms (6 days) | alsford |
Tb927.4.1950 | Trypanosoma brucei | no significant loss or gain of fitness in procyclic forms | alsford |
Tb927.4.1950 | Trypanosoma brucei | no significant loss or gain of fitness in differentiation of procyclic to bloodstream forms | alsford |
YPR048W | Saccharomyces cerevisiae | inviable | yeastgenome |
TGME49_249320 | Toxoplasma gondii | Probably essential | sidik |
gerdes | Experimental determination and system-level analysis of essential genes in E. coli MG1655 | Gerdes et al., J Bacteriol. 2003 185:5673-84 |
keio | Systematic single-gene knock-out mutants of E. coli K12 | The Keio Collection |
alsford | High-throughput phenotyping using parallel sequencing of RNA interference targets in the African trypanosome | Genome Res 2011, 21:915-924 |
neb | C. elegans RNAi phenotypes | Data obtained from Wormbase WS150, curated by K. Chaudary and T. Carlow, New England Biolabs |
wormbase | C. elegans RNAi experiments | WormBase web site, http://www.wormbase.org, release WS170 |
blattner | Systematic mutagenesis of the E. coli (MG1655) genome | J Bacteriol 2004, 186:4921-4930 |
yeastgenome | Systematic deletion of yeast genes | Saccharomyces Genome Database |
nmpdr | Genome-scale essentiality datasets from published studies (M. tuberculosis) | National Microbial Pathogen Data Resource |
shigen | Profiling of E. coli Chromosome (PEC) | National Institute of Genetics, Japan |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.